Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis

NCT ID: NCT04953286

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-17

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefore essential for a better understanding of the pathophysiology of ALS, which remains poorly understood, and also for better clinical management. The ocular surface, made up of liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases such as Parkinson's or Alzheimer's. To date, no study has explored the ocular surface as a biomarker in ALS

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Amyotrophic Lateral Sclerosis Biomarkers Ocular Surface Tear

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case group

The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients with Amyotrophic Lateral Sclerosis

Group Type OTHER

Measure of visual acuity

Intervention Type OTHER

ETDRS and Parinaud scale

Interferometry

Intervention Type OTHER

Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus

Samples of basal tears

Intervention Type OTHER

Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary

Central corneal sensitivity

Intervention Type OTHER

Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)

Slit lamp examination and undilated fundus

Intervention Type OTHER

Slit lamp examination and undilated fundus

Conjunctival impression

Intervention Type OTHER

Conjunctival impression with anesthetic instillation

Evaluation of the corneal innervation

Intervention Type OTHER

Contact corneal confocal microscopy

Control group

The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients without neurological disease

Group Type OTHER

Measure of visual acuity

Intervention Type OTHER

ETDRS and Parinaud scale

Interferometry

Intervention Type OTHER

Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus

Samples of basal tears

Intervention Type OTHER

Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary

Central corneal sensitivity

Intervention Type OTHER

Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)

Slit lamp examination and undilated fundus

Intervention Type OTHER

Slit lamp examination and undilated fundus

Conjunctival impression

Intervention Type OTHER

Conjunctival impression with anesthetic instillation

Evaluation of the corneal innervation

Intervention Type OTHER

Contact corneal confocal microscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measure of visual acuity

ETDRS and Parinaud scale

Intervention Type OTHER

Interferometry

Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus

Intervention Type OTHER

Samples of basal tears

Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary

Intervention Type OTHER

Central corneal sensitivity

Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)

Intervention Type OTHER

Slit lamp examination and undilated fundus

Slit lamp examination and undilated fundus

Intervention Type OTHER

Conjunctival impression

Conjunctival impression with anesthetic instillation

Intervention Type OTHER

Evaluation of the corneal innervation

Contact corneal confocal microscopy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with clinically defined or probable primary ALS according to Airlie House criteria(1)
* Familial or sporadic form
* ≥18 years of age
* Patient affiliated with a social security plan
* Informed consent signed by the patient


* No diagnosed neurological pathology
* ≥18 years of age
* Patient affiliated with a social security plan
* Informed consent signed by the participant

Exclusion Criteria

* Motor neuron disease mimicking ALS
* Pregnant or breastfeeding woman
* Treatment that may have a neuroprotective effect
* Any eye drops or treatments that may interfere with tear production
* Lens wearer
* Eye surgery ≤3 months
* Any ocular pathology other than ametropia, oculomotor disorder, amblyopia
* Any general pathology other than ALS with ocular repercussions
* Protective measure of guardianship or curators

Control group selection criteria:


* Pregnant or breastfeeding woman
* Treatment likely to have a neuroprotective effect
* Any eye drops or treatments that may interfere with tear production
* Lens wearer
* Eye surgery ≤3 months
* Any ocular pathology except ametropia, oculomotor disorder, amblyopia
* Any general pathology with ocular repercussions
* Protective measure of guardianship or curator
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ophthalmology Department, University Hospital of Tours, France

Tours, , France

Site Status

Neurology Department, University Hospital of Tours, France

Tours, , France

Site Status

Centre d'Investigation Clinique_CIC 1415

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Khanna RK, Catanese S, Mortemousque G, Dupuy C, Lefevre A, Emond P, Beltran S, Gissot V, Pisella PJ, Blasco H, Corcia P. Metabolomics of basal tears in amyotrophic lateral sclerosis: A cross-sectional study. Ocul Surf. 2024 Oct;34:363-369. doi: 10.1016/j.jtos.2024.09.005. Epub 2024 Sep 28.

Reference Type RESULT
PMID: 39349171 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DR210051

Identifier Type: -

Identifier Source: org_study_id